Literature DB >> 23023715

Hodgkin lymphoma.

Ralf Küppers1, Andreas Engert, Martin-Leo Hansmann.   

Abstract

Hodgkin lymphoma (HL), a B cell-derived cancer, is one of the most common lymphomas. In HL, the tumor cells--Hodgkin and Reed-Sternberg (HRS) cells--are usually very rare in the tissue. Although HRS cells are derived from mature B cells, they have largely lost their B cell phenotype and show a very unusual co-expression of markers of various hematopoietic cell types. HRS cells show deregulated activation of multiple signaling pathways and transcription factors. The activation of these pathways and factors is partly mediated through interactions of HRS cells with various other types of cells in the microenvironment, but also through genetic lesions. The transforming events involved in the pathogenesis of HL are only partly understood, but mutations affecting the NF-κB and JAK/STAT pathways are frequent. The dependency of HRS cells on microenvironmental interactions and deregulated signaling pathways may offer novel strategies for targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23023715      PMCID: PMC3534167          DOI: 10.1172/JCI61245

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  115 in total

1.  Clonotypic B cells in classic Hodgkin lymphoma.

Authors:  Ralf Küppers
Journal:  Blood       Date:  2009-10-29       Impact factor: 22.113

2.  Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.

Authors:  Boris Böll; Peter Borchmann; Max S Topp; Mathias Hänel; Katrin S Reiners; Andreas Engert; Ralph Naumann
Journal:  Br J Haematol       Date:  2009-10-15       Impact factor: 6.998

3.  Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma.

Authors:  Jessica A Shafer; Conrad R Cruz; Ann M Leen; Stephanie Ku; An Lu; Alexandra Rousseau; Helen E Heslop; Cliona M Rooney; Catherine M Bollard; Aaron E Foster
Journal:  Leuk Lymphoma       Date:  2010-05

4.  Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma.

Authors:  Alfons Navarro; Tania Diaz; Antonio Martinez; Anna Gaya; Aina Pons; Bernat Gel; Carles Codony; Gerardo Ferrer; Carmen Martinez; Emili Montserrat; Mariano Monzo
Journal:  Blood       Date:  2009-08-07       Impact factor: 22.113

5.  A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.

Authors:  Patrick B Johnston; David J Inwards; Joseph P Colgan; Betsy R Laplant; Brian F Kabat; Thomas M Habermann; Ivana N Micallef; Luis F Porrata; Stephen M Ansell; Craig B Reeder; Vivek Roy; Thomas E Witzig
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

6.  Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs.

Authors:  Pieter Van Vlierberghe; An De Weer; Pieter Mestdagh; Tom Feys; Katleen De Preter; Pascale De Paepe; Kathleen Lambein; Jo Vandesompele; Nadine Van Roy; Bruno Verhasselt; Bruce Poppe; Frank Speleman
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

7.  Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells.

Authors:  Stephen J Salipante; Matthew E Mealiffe; Jeremy Wechsler; Maxwell M Krem; Yajuan Liu; Shinae Namkoong; Govind Bhagat; Tomas Kirchhoff; Kenneth Offit; Henry Lynch; Peter H Wiernik; Mikhail Roshal; Mary Lou McMaster; Margaret Tucker; Jonathan R Fromm; Lynn R Goldin; Marshall S Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

8.  Mutations in the genes coding for the NF-κB regulating factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma.

Authors:  Martin A Schumacher; Roland Schmitz; Verena Brune; Enrico Tiacci; Claudia Döring; Martin-Leo Hansmann; Reiner Siebert; Ralf Küppers
Journal:  Haematologica       Date:  2009-07-31       Impact factor: 9.941

9.  Highly increased familial risks for specific lymphoma subtypes.

Authors:  Lynn R Goldin; Magnus Björkholm; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Br J Haematol       Date:  2009-05-04       Impact factor: 6.998

10.  Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases.

Authors:  Annette Lake; Lesley A Shield; Pablo Cordano; Daniel T Y Chui; Julie Osborne; Shauna Crae; Katherine S Wilson; Sabrina Tosi; Samantha J L Knight; Stefan Gesk; Reiner Siebert; Ron T Hay; Ruth F Jarrett
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

View more
  93 in total

Review 1.  CAR-T Cell Therapy for Lymphoma.

Authors:  Carlos A Ramos; Helen E Heslop; Malcolm K Brenner
Journal:  Annu Rev Med       Date:  2015-08-26       Impact factor: 13.739

2.  Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma.

Authors:  Marta Celegato; Cinzia Borghese; Naike Casagrande; Maurizio Mongiat; Xaver U Kahle; Alice Paulitti; Michele Spina; Alfonso Colombatti; Donatella Aldinucci
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113

3.  Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  S Hartmann; B Schuhmacher; T Rausch; L Fuller; C Döring; M Weniger; A Lollies; C Weiser; L Thurner; B Rengstl; U Brunnberg; M Vornanen; M Pfreundschuh; V Benes; R Küppers; S Newrzela; M-L Hansmann
Journal:  Leukemia       Date:  2015-12-10       Impact factor: 11.528

4.  Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis.

Authors:  Thomas Sommermann; Tomoharu Yasuda; Jonathan Ronen; Tristan Wirtz; Timm Weber; Ulrike Sack; Rebecca Caeser; Jingwei Zhang; Xun Li; Van Trung Chu; Anna Jauch; Kristian Unger; Daniel J Hodson; Altuna Akalin; Klaus Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-10       Impact factor: 11.205

5.  WNT5A: a motility-promoting factor in Hodgkin lymphoma.

Authors:  F Linke; S Zaunig; M M Nietert; F von Bonin; S Lutz; C Dullin; P Janovská; T Beissbarth; F Alves; W Klapper; V Bryja; T Pukrop; L Trümper; J Wilting; D Kube
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

6.  The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing.

Authors:  Y Liu; F R Abdul Razak; M Terpstra; F C Chan; A Saber; M Nijland; G van Imhoff; L Visser; R Gascoyne; C Steidl; J Kluiver; A Diepstra; K Kok; A van den Berg
Journal:  Leukemia       Date:  2014-06-20       Impact factor: 11.528

Review 7.  [Malignant lymphomas in children and adolescents. Practical knowledge for diagnosis].

Authors:  I Oschlies; W Klapper
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

8.  High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders.

Authors:  Antonella Caivano; Ilaria Laurenzana; Luciana De Luca; Francesco La Rocca; Vittorio Simeon; Stefania Trino; Fiorella D'Auria; Antonio Traficante; Maddalena Maietti; Tiziana Izzo; Giovanni D'Arena; Giovanna Mansueto; Giuseppe Pietrantuono; Luca Laurenti; Pellegrino Musto; Luigi Del Vecchio
Journal:  Tumour Biol       Date:  2015-07-09

9.  Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma.

Authors:  Stephen J Salipante; Andrew Adey; Anju Thomas; Choli Lee; Yajuan J Liu; Akash Kumar; Alexandra P Lewis; David Wu; Jonathan R Fromm; Jay Shendure
Journal:  Genes Chromosomes Cancer       Date:  2015-12-09       Impact factor: 5.006

Review 10.  Mechanisms underlying the association between obesity and Hodgkin lymphoma.

Authors:  Andreia Matos; Joana Marinho-Dias; Sofia Ramalheira; Maria José Oliveira; Manuel Bicho; Ricardo Ribeiro
Journal:  Tumour Biol       Date:  2016-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.